NICE now finds Firmagon (degarelix) to be not cost effective as a prostate cancer treatment- Ferring
The National Institute for Care and Clinical Excellence (NICE) has reversed an earlier decision regarding Firmagon (degarelix) from Ferring and concluded that the drug is not a cost-effective treatment for advanced, hormone-dependent prostate cancer compared with the current standard of care. The independent Appraisal Committee of NICE had previously provisionally supported the drug’s use in patients with signs and symptoms of spinal cord compression, but clinical experts said that using the treatment at this stage would not be appropriate.
Related news and insights
Amicus Therapeutics announced that the European Medicines Agency validated the Marketing Authorization Applications (MAA) for AT GAA (cipaglucosidase alfa + miglustat), the Company’s investigational two-component therapy for the treatment of Pompe disease.
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
BeiGene, Ltd. and EUSA Pharma (UK), Ltd. announced that the China National Medical Products Administration (NMPA) has approved Sylvant (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD).